Japanese Healthtech Stock News

Konica Minolta (TSE:4902) has drawn fresh attention after reporting nine-month earnings to December 31, 2025, with net income of ¥21,436 million compared to a net loss of ¥13,399 million a year earlier. See our latest analysis for Konica Minolta. The earnings announcement appears to have given the share price a short term lift, with a 1 day share price return of 3.38% to ¥624.0. However, the 30 day share price return of 10.95% and year to date share price return of 9.64% are weaker, while the...

San-in Godo Bank Ltd (TSE:8381) is back on investor radars after reporting higher net income and earnings per share for the nine months to December 31, 2025, alongside an increased year-end dividend. See our latest analysis for San-in Godo BankLtd. The earnings beat, higher year end dividend of ¥28.00 per share, and completion of the ¥999.88m share buyback appear to have gone hand in hand with stronger momentum, with a 90 day share price return of 26.63% and a 1 year total shareholder return...

Duskin (TSE:4665) has been back in focus after it agreed a master franchise deal to reintroduce the Mister Donut brand to East China, alongside reporting nine month earnings that showed higher sales and net income year on year. See our latest analysis for Duskin. The Mister Donut re entry into East China and the latest nine month earnings update appear to have contributed to growing momentum, with Duskin’s 90 day share price return of 11.76% alongside a 1 year total shareholder return of...

If you are wondering whether Takeda Pharmaceutical's share price still offers value after its recent performance, this article will walk through what the current market price might be implying. The stock last closed at ¥5,565, with returns of 2.7% over 7 days, 9.5% over 30 days, 13.2% year to date, 41.7% over 1 year and 50.5% over 3 years. These figures may catch the eye of investors thinking about growth potential or shifts in risk perception. Recent news flow around Takeda Pharmaceutical...

In early February 2026, Startale Group and SBI Holdings launched Strium, a blockchain-based exchange infrastructure designed for 24/7 trading and settlement of tokenized equities and real-world asset-linked instruments across spot and derivatives markets in Asia, while keeping issuance and custody separate for compatibility with existing financial systems. A day earlier, SBI Holdings reported that for the nine months ended December 31, 2025, sales rose to ¥1.49 trillions and net income to...

Why Mitsui Fudosan’s latest earnings matter for shareholders Mitsui Fudosan (TSE:8801) just reported nine month results to December 31, 2025, alongside an upward revision to full year earnings forecasts, putting fresh attention on how the real estate group’s fundamentals stack up. See our latest analysis for Mitsui Fudosan. The earnings beat and upgraded guidance on 6 February sit alongside a sharp pick up in momentum, with a 7 day share price return of 17.11% and a 1 year total shareholder...

Sumco Corporation recently held its 2025 earnings call and a board meeting on February 10, 2026, to review performance and decide on personnel changes. The combination of financial disclosure and potential leadership adjustments offers fresh insight into how Sumco may be positioning its operations and governance. We will now examine how the earnings call and its focus on personnel changes could influence Sumco's broader investment narrative. Invest in the nuclear renaissance through our list...

In January 2026, Shin-Etsu Chemical Co., Ltd. reported nine-month results to December 31, 2025, with sales of ¥1.93 trillion and lower net income of ¥384.32 billion year-on-year. On the same day, the board approved a secondary share offering, highlighting management’s decision to tap equity markets while earnings momentum softened. We’ll now examine how the earnings softness alongside the newly approved secondary share offering may influence Shin-Etsu Chemical’s investment narrative. Find 22...

Keio (TSE:9008) has posted Q3 2026 revenue of ¥129.5 billion with basic EPS of ¥98.09, providing another reference point in a year where trailing net margin has eased back to 7.7%. Over the past few quarters, revenue has moved from ¥120.7 billion in Q3 2025 to ¥118.0 billion in Q4 2025, then to ¥113.7 billion in Q1 2026, ¥117.0 billion in Q2 2026 and now ¥129.5 billion in Q3 2026. EPS shifted from ¥115.71 to ¥30.94, then ¥101.27, ¥82.41 and most recently ¥98.09, leaving investors weighing...

How Recruit Holdings’ Latest Numbers Set the Stage for the Next Chapter Recruit Holdings (TSE:6098) has put up another busy quarter, with Q3 2026 revenue at ¥943.2b and basic EPS of ¥103.62, set against trailing twelve month revenue of ¥3.60t and EPS of ¥320.64 that frame the scale of the business today. The company has seen quarterly revenue move from ¥896.99b in Q3 2025 to ¥943.20b in Q3 2026, while basic EPS shifted from ¥80.11 to ¥103.62 over the same period, and trailing twelve month net...

In late January 2026, MISUMI Group Inc. raised its full-year earnings and dividend guidance for the fiscal year ending March 31, 2026, after reporting higher nine-month sales of ¥320,661 million but lower net income of ¥23,027 million compared with the same period a year earlier. The guidance revision highlights the steady contribution from proprietary initiatives and newly consolidated Fictiv Inc., alongside the earnings impact of a prolonged depreciation of the yen, even as demand from key...

In late January 2026, Metaplanet Inc. approved a large follow-on equity offering of 24,530,000 ordinary shares at ¥499 each, with attached warrants and a planned subsequent direct listing, alongside board resolutions on AGM timing and preferred share dividends. This capital raise of about ¥12.24 billions, paired with continued dividends on Class B preferred shares, highlights a simultaneous focus on funding and maintaining commitments to existing investors. Against this backdrop, we will...

ORIX (TSE:8591) has put up another busy quarter, with Q3 2026 revenue at ¥844,413 million and Basic EPS of ¥106.67, backed by trailing twelve month revenue of ¥3.1 trillion and EPS of ¥416.98. The company has seen revenue move from ¥750,851 million in Q3 2025 to ¥844,413 million in Q3 2026, while trailing twelve month EPS shifted from ¥347.79 to ¥416.98, alongside a net margin of 15% versus 13.6% a year earlier that frames this update as a profitability focused story for investors. See our...

Tokyo Ohka Kogyo (TSE:4186) has come into focus after the company raised its FY2025 consolidated earnings guidance, citing stronger semiconductor demand linked to generative AI and currency effects that support higher projected sales and profits. See our latest analysis for Tokyo Ohka Kogyo. The raised guidance and upcoming earnings call have arrived after a strong run, with a 30 day share price return of 36.03% and a 1 year total shareholder return of 138.22%, suggesting momentum has been...

Why Santen Pharmaceutical’s Latest Earnings Matter for Shareholders Santen Pharmaceutical (TSE:4536) has put fresh numbers on the table, reporting nine month sales of ¥210,763 million and net income of ¥21,816 million, both below the prior year’s levels. Earnings per share from continuing operations also softened, with basic EPS at ¥66.16 and diluted EPS at ¥66.05, compared with ¥78.21 and ¥77.98 a year earlier. This represents a shift many investors are now reassessing. See our latest...

Kissei Pharmaceutical (TSE:4547) has drawn investor attention after a board meeting on January 30, 2026 approved commemorative dividends alongside nine month results showing higher sales, net income, and earnings per share compared with a year earlier. See our latest analysis for Kissei Pharmaceutical. The latest commemorative dividend news and earnings update come after a solid 13.32% 90 day share price return and a 31.64% 1 year total shareholder return, which indicates that momentum has...

Eisai (TSE:4523) has put another set of numbers on the board for Q3 2026, with revenue of ¥219.9 billion and basic EPS of ¥60.94, anchored by net income of ¥17,178 million. The company has seen quarterly revenue move between ¥188.2 billion and ¥219.9 billion over the past six reported periods, while basic EPS ranged from ¥3.36 to ¥84.31. This gives investors a clear view of how the top line and EPS have tracked through recent quarters as they weigh the latest release against its earnings...

Alps Alpine (TSE:6770) has drawn fresh attention after reporting nine month sales of ¥761,189 million and net income of ¥23,962 million, along with increased full year guidance and a planned dividend hike. See our latest analysis for Alps Alpine. The earnings beat, upgraded guidance and higher dividend have come alongside a 12.38% 1 month share price return and a 44.22% 1 year total shareholder return. This suggests momentum has been building as investors reassess Alps Alpine’s outlook and...

Macnica Holdings (TSE:3132) updated its outlook after nine month results, lifting full year net sales guidance to ¥1,200b while trimming operating income expectations because its autonomous driving bus business is progressing more slowly than planned. See our latest analysis for Macnica Holdings. The guidance revision and nine month earnings sit against a share price of ¥2,586.5, with a 30 day share price return of 4.42% and a 1 year total shareholder return of 47%, suggesting momentum has...

Earnings and dividend revisions put Fujitsu (TSE:6702) in focus Fujitsu (TSE:6702) has drawn investor attention after reporting stronger nine month results to December 31, 2025, paired with higher full year earnings guidance and a revised dividend forecast reflecting increased free cash flow. See our latest analysis for Fujitsu. Despite the earnings and dividend revisions, Fujitsu’s recent share price performance has been softer, with a 7 day share price return showing a decline of 6.76% and...

Furukawa Electric (TSE:5801) has just posted its Q3 2026 numbers, with revenue of ¥338.2b and basic EPS of ¥320.65, alongside trailing 12 month revenue of ¥1.27t and EPS of ¥745.67 that sit against a reported 78.7% earnings growth over the past year. The company has seen quarterly revenue move from ¥296.8b and EPS of ¥92.49 in Q2 2025 to ¥338.2b and EPS of ¥320.65 in Q3 2026. Trailing 12 month net income, including a ¥23.8b one off gain, stands at ¥52.5b. For investors, the key question is...

As global markets experience a mix of volatility and gains, with small-cap and value-oriented stocks showing strength amid cooling labor market signals in the U.S., investors are closely monitoring the impact of artificial intelligence on high-growth tech sectors. In this dynamic environment, identifying promising tech stocks involves considering not only their innovative potential but also how they navigate economic shifts and investor sentiment.

As global markets navigate a period of volatility, characterized by mixed performances across major indices and concerns over AI's disruptive potential, investors are increasingly seeking stability through value-oriented segments. In such an environment, dividend stocks can offer a reliable income stream and potential for capital appreciation, making them an attractive option for those looking to balance growth with income amidst economic fluctuations.

Nissan Chemical (TSE:4021) has released a detailed scorecard for Q3 2026, reporting revenue of ¥65,341 million and basic EPS of ¥90.67, supported by net income of ¥12,216 million for the quarter. The company’s revenue increased from ¥56,647 million in Q3 2025 to ¥65,341 million in Q3 2026, while EPS moved from ¥81.51 to ¥90.67 over the same period. Investors may weigh these higher headline figures against indications of slightly softer profit margins over the year. See our full analysis for...